TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06942442: A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

Sponsor: Sarcoma Alliance for Research through Collaboration · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 47 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,339,800

Rescue Site Savings

+$877,800

Unlock Full NCT06942442 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06942442 Rescue Dossier →